Agios Pharm Net Income
| AGIO Stock | USD 28.07 0.36 1.30% |
As of the 13th of February 2026, Agios Pharm shows the Standard Deviation of 7.27, mean deviation of 3.11, and Risk Adjusted Performance of (0.01). Agios Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Agios Pharm Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 15.7963 | Revenue | Earnings Share (7.01) |
| Last Reported | Projected for Next Year | ||
| Net Income | 606.4 M | 636.7 M | |
| Net Income From Continuing Ops | 774.8 M | 813.5 M | |
| Net Loss | -266.6 M | -253.2 M | |
| Net Loss | (7.12) | (6.76) | |
| Net Income Per E B T | 1.00 | 1.05 |
Agios | Net Income | Build AI portfolio with Agios Stock |
Evaluating Agios Pharm's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Agios Pharm's fundamental strength.
Latest Agios Pharm's Net Income Growth Pattern
Below is the plot of the Net Income of Agios Pharm over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Agios Pharm financial statement analysis. It represents the amount of money remaining after all of Agios Pharm operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Agios Pharm's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Agios Pharm's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 673.73 M | 10 Years Trend |
|
Net Income |
| Timeline |
Agios Net Income Regression Statistics
| Arithmetic Mean | 82,746,452 | |
| Coefficient Of Variation | 669.26 | |
| Mean Deviation | 415,971,868 | |
| Median | (53,504,000) | |
| Standard Deviation | 553,785,395 | |
| Sample Variance | 306678.3T | |
| Range | 2B | |
| R-Value | 0.42 | |
| Mean Square Error | 268221.2T | |
| R-Squared | 0.18 | |
| Significance | 0.09 | |
| Slope | 46,535,220 | |
| Total Sum of Squares | 4906852.2T |
Agios Net Income History
Other Fundumenentals of Agios Pharm
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Agios Pharm Net Income component correlations
Agios Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Agios Pharm is extremely important. It helps to project a fair market value of Agios Stock properly, considering its historical fundamentals such as Net Income. Since Agios Pharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Agios Pharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Agios Pharm's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Agios diversify its offerings? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Agios Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.437 | Return On Assets | Return On Equity |
Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Agios Pharm 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Agios Pharm's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Agios Pharm.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Agios Pharm on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Agios Pharm or generate 0.0% return on investment in Agios Pharm over 90 days. Agios Pharm is related to or competes with Denali Therapeutics, Recursion Pharmaceuticals, Beam Therapeutics, Arcus Biosciences, Cogent Biosciences, Immunitybio, and Galapagos. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the f... More
Agios Pharm Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Agios Pharm's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Agios Pharm upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 56.88 | |||
| Value At Risk | (3.94) | |||
| Potential Upside | 5.99 |
Agios Pharm Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Agios Pharm's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Agios Pharm's standard deviation. In reality, there are many statistical measures that can use Agios Pharm historical prices to predict the future Agios Pharm's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.19) |
Agios Pharm February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 3.11 | |||
| Coefficient Of Variation | (3,738) | |||
| Standard Deviation | 7.27 | |||
| Variance | 52.91 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 56.88 | |||
| Value At Risk | (3.94) | |||
| Potential Upside | 5.99 | |||
| Skewness | (5.01) | |||
| Kurtosis | 37.54 |
Agios Pharm Backtested Returns
Agios Pharm secures Sharpe Ratio (or Efficiency) of -0.052, which signifies that the company had a -0.052 % return per unit of risk over the last 3 months. Agios Pharm exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Agios Pharm's Mean Deviation of 3.11, risk adjusted performance of (0.01), and Standard Deviation of 7.27 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.1, which signifies a somewhat significant risk relative to the market. Agios Pharm returns are very sensitive to returns on the market. As the market goes up or down, Agios Pharm is expected to follow. At this point, Agios Pharm has a negative expected return of -0.39%. Please make sure to confirm Agios Pharm's skewness, and the relationship between the total risk alpha and rate of daily change , to decide if Agios Pharm performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Agios Pharm has insignificant reverse predictability. Overlapping area represents the amount of predictability between Agios Pharm time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Agios Pharm price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Agios Pharm price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | 0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.44 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Agios Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Agios Pharm reported net income of 673.73 M. This is 97.41% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 17.99% lower than that of the firm.
Agios Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Agios Pharm's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Agios Pharm could also be used in its relative valuation, which is a method of valuing Agios Pharm by comparing valuation metrics of similar companies.Agios Pharm is currently under evaluation in net income category among its peers.
Agios Pharm Current Valuation Drivers
We derive many important indicators used in calculating different scores of Agios Pharm from analyzing Agios Pharm's financial statements. These drivers represent accounts that assess Agios Pharm's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Agios Pharm's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 2.0B | 1.5B | 1.2B | 1.6B | 1.4B | 1.6B | |
| Enterprise Value | 1.9B | 1.5B | 1.2B | 1.5B | 1.4B | 1.5B |
Agios Pharm ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Agios Pharm's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Agios Pharm's managers, analysts, and investors.Environmental | Governance | Social |
Agios Pharm Institutional Holders
Institutional Holdings refers to the ownership stake in Agios Pharm that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Agios Pharm's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Agios Pharm's value.| Shares | Paradigm Biocapital Advisors Lp | 2025-06-30 | 1.1 M | Bank Of America Corp | 2025-06-30 | 1.1 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.1 M | Citadel Advisors Llc | 2025-06-30 | 1.1 M | Caligan Partners Lp | 2025-06-30 | 1.1 M | Jpmorgan Chase & Co | 2025-06-30 | 1 M | Bnp Paribas Investment Partners Sa | 2025-06-30 | 1 M | Rock Springs Capital Management Lp | 2025-06-30 | 989.7 K | Deutsche Bank Ag | 2025-06-30 | 921.6 K | Farallon Capital Management, L.l.c. | 2025-06-30 | 5.8 M | Vanguard Group Inc | 2025-06-30 | 5.7 M |
Agios Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (9.07) % | ||||
| Current Valuation | 707.53 M | ||||
| Shares Outstanding | 58.31 M | ||||
| Shares Owned By Insiders | 1.74 % | ||||
| Shares Owned By Institutions | 98.26 % | ||||
| Number Of Shares Shorted | 6.73 M | ||||
| Price To Earning | 1.26 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 36.08 X | ||||
| Revenue | 36.5 M | ||||
| Gross Profit | (295.22 M) | ||||
| EBITDA | (420.08 M) | ||||
| Net Income | 673.73 M | ||||
| Cash And Equivalents | 819.31 M | ||||
| Cash Per Share | 14.95 X | ||||
| Total Debt | 56.99 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 17.98 X | ||||
| Book Value Per Share | 22.04 X | ||||
| Cash Flow From Operations | (389.84 M) | ||||
| Short Ratio | 7.08 X | ||||
| Earnings Per Share | (7.01) X | ||||
| Target Price | 36.63 | ||||
| Number Of Employees | 486 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 1.62 B | ||||
| Total Asset | 1.66 B | ||||
| Retained Earnings | (148.92 M) | ||||
| Working Capital | 884.44 M | ||||
| Current Asset | 337.33 M | ||||
| Current Liabilities | 52.89 M | ||||
| Net Asset | 1.66 B |
About Agios Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agios Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
| 0.64 | DSGN | Design Therapeutics | PairCorr |
| 0.45 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.42 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Will Biotechnology sector continue expanding? Could Agios diversify its offerings? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Agios Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.437 | Return On Assets | Return On Equity |
Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.